Evaluation of novel tuberculosis LAM assays among people living with HIV and sepsis
HIV 感染者和败血症患者中新型结核病 LAM 检测的评估
基本信息
- 批准号:10548256
- 负责人:
- 金额:$ 24.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-21 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAccountingAcquired Immunodeficiency SyndromeAddressAffinityAfrica South of the SaharaAntigensAntitubercular AgentsBiological AssayBloodCD4 Lymphocyte CountCase Fatality RatesCause of DeathCell WallCessation of lifeCharacteristicsClinicalCoupledCritical IllnessDevelopmentDiagnosisDiagnosticDiagnostic testsDiseaseDoseEpidemiologyEtiologyEvaluationFunctional disorderGenus MycobacteriumGoalsHIVHIV/TBHospitalizationImmunologic Deficiency SyndromesInfrastructureInterventionIntervention TrialLifeLipopolysaccharidesLungMethodsMicrobiologyMonoclonal AntibodiesMycobacterium tuberculosisOrganOutcomeParentsPatientsPerformancePersonsPharmaceutical PreparationsPopulationProcessProtocols documentationRandomizedRandomized Clinical TrialsRandomized Controlled TrialsReference StandardsReportingResearchSensitivity and SpecificitySepsisSilverSiteSpecificitySpecimenSpecimen HandlingSputumSymptomsSyndromeTanzaniaTechnologyTestingTimeTuberculosisTuberculosis diagnosisUgandaUndifferentiatedUnited States National Institutes of HealthUrineVulnerable PopulationsWorkWorld Health Organizationaccurate diagnosisbaseclinical implementationclinical practiceclinically relevantcomparativedesigndiagnostic accuracyearly phase clinical trialimprovedinsightlateral flow assaylipoarabinomannanmortalitymultiplex assaynovelparticlepathogenperformance testspoint of careprospectiverandomized trialrapid teststandard of caresurvival outcometreatment armtrial designtuberculosis diagnosticstuberculosis treatmentuptakeurinary
项目摘要
PROJECT SUMMARY/ABSTRACT
Mycobacterium tuberculosis is a leading cause of sepsis and the leading killer among people living with HIV
(PLWH) in sub-Saharan Africa. The diagnosis of tuberculosis (TB) is challenging to confirm in this population
due to the paucibacillary and disseminated disease state, coupled with a frequent inability to produce sputum
even among those with a pulmonary focus of TB. There is a pressing need for improved TB diagnostics,
particularly those that rely on readily-available specimens such as urine. One example of this is the AlereLAM
assay, which detects a TB cell-wall fragment (lipoarabinomannan, or “LAM”) from urine. The AlereLAM has been
endorsed by the World Health Organization (WHO) since 2015 and performs relatively well among people with
advanced HIV/AIDS, however the sensitivity is still modest at 56%. The Fujifilm SILVAMP is a newer urinary
LAM assay that uses high affinity monoclonal antibodies and a silver amplification step to aid interpretation. Early
studies have demonstrated improved sensitivity at 71% among PLWH, but the assay has not yet been tested
among a subset of PLWH who present with undifferentiated sepsis. There is room for improvement in the
accuracy of these assays. Therefore, we will evaluate the ability for a ~30 minute urine processing step, using
the Ceres Nanotrap, to augment the yield of these rapid urinary LAM assays. This project serves as a substudy
of the ATLAS Trial, a randomized controlled trial using a 2x2 factorial design of immediate empiric anti-TB
therapy initiation and sepsis-specific doses of anti-TB therapy along with standard of care among people living
with HIV who present with sepsis to our collaborative sites in Tanzania and Uganda. We will compare the
performance between the AlereLAM and SILVAMP assays before and after processing the urine with the Ceres
Nanotrap which concentrates urinary LAM and removes interfering substances within the urine. We will also
evaluate the diagnostic accuracy and incremental yield of rapid assays to detect urinary LAM as compared to
robust diagnostic reference standards (including blood/sputum culture for TB, sputum smear and TB-PCR
testing, bacterial culture of blood/sputum/urine, as well as a novel multiplex PCR assay to identify the etiology of
sepsis from blood and TB-PCR testing of urine) that are designed to identify TB and non-TB etiologies of sepsis,
as well as a clinical reference standard that is partly informed by the ATLAS Trial interventions and outcomes.
We will leverage the interventional ATLAS trial design and pursue exploratory analyses to understand the
epidemiologic impact of a more accurate, rapid, TB diagnostic as well as the clinical impact of timelier initiation
of anti-TB treatment on mortality. Our work within this unique trial infrastructure can inherently hasten the
implementation of improved urinary TB diagnostics into clinical practice in settings with high TB/HIV burden for
critically ill people.
项目概要/摘要
结核分枝杆菌是脓毒症的主要原因,也是艾滋病毒感染者的头号杀手
撒哈拉以南非洲地区的艾滋病感染者(PLWH)。在该人群中确诊结核病 (TB) 具有挑战性
由于少杆菌和播散性疾病状态,加上经常无法产生痰
即使是那些患有肺结核病灶的人。迫切需要改进结核病诊断,
特别是那些依赖尿液等现成样本的样本。 AlereLAM 就是这方面的一个例子
检测,从尿液中检测结核细胞壁碎片(阿拉伯脂甘露聚糖,或“LAM”)。 AlereLAM 已
自 2015 年起获得世界卫生组织 (WHO) 认可,在患有以下疾病的人群中表现相对较好
晚期 HIV/AIDS,但敏感性仍然较低,为 56%。 Fujifilm SILVAMP 是一款新型泌尿系统
LAM 测定使用高亲和力单克隆抗体和银扩增步骤来帮助解释。早期的
研究表明 PLWH 的敏感性提高了 71%,但该检测方法尚未经过测试
出现未分化败血症的 PLWH 子集。方面还有改进的余地
这些测定的准确性。因此,我们将使用以下方法评估约 30 分钟尿液处理步骤的能力
Ceres Nanotrap,以提高这些快速尿液 LAM 检测的产量。该项目作为子研究
ATLAS 试验是一项随机对照试验,采用 2x2 因子设计立即进行经验性抗结核治疗
治疗开始和脓毒症特异性抗结核治疗剂量以及居住者的护理标准
患有败血症的艾滋病毒感染者来到我们在坦桑尼亚和乌干达的合作地点。我们将比较
使用 Ceres 处理尿液之前和之后 AlereLAM 和 SILVAMP 检测的性能
Nanotrap 可浓缩尿液中的 LAM 并去除尿液中的干扰物质。我们还将
与相比,评估快速检测尿 LAM 的诊断准确性和增量产量
稳健的诊断参考标准(包括结核病血液/痰培养、痰涂片和结核病聚合酶链反应(TB-PCR)
测试、血液/痰/尿液细菌培养,以及新型多重 PCR 检测来确定病因
血液脓毒症和尿液 TB-PCR 检测),旨在识别脓毒症的结核病和非结核病病因,
以及部分来自 ATLAS 试验干预措施和结果的临床参考标准。
我们将利用介入性 ATLAS 试验设计并进行探索性分析来了解
更准确、更快速的结核病诊断对流行病学的影响以及更及时启动的临床影响
抗结核治疗对死亡率的影响。我们在这个独特的试验基础设施中的工作本质上可以加速
在结核病/艾滋病毒负担高的环境中将改进的尿结核诊断应用于临床实践
危重病人。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tania A Thomas其他文献
Leveraging nutritional rehabilitation and tuberculosis programmes to tackle tuberculosis and severe acute malnutrition in children
利用营养康复和结核病方案来解决儿童结核病和严重急性营养不良问题
- DOI:
10.1016/s2352-4642(25)00062-8 - 发表时间:
2025-05-01 - 期刊:
- 影响因子:15.500
- 作者:
Bryan J Vonasek;Olivier Marcy;Jasmine Armour-Marshall;Martina Casenghi;Cécile Cazes;Mohammod Jobayer Chisti;Marc d’Elbée;Helena Huerga;Cathy Hewison;Christina L Lancioni;Patrick S Lungu;Eric D McCollum;Victor Musiime;Tisungane Mvalo;James A Seddon;Andrew P Steenhoff;Tania A Thomas;Marco Tovar;Anca Vasiliu;Anthony Garcia-Prats;Chishala Chabala - 通讯作者:
Chishala Chabala
Tania A Thomas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tania A Thomas', 18)}}的其他基金
Evaluation of novel tuberculosis LAM assays among people living with HIV and sepsis
HIV 感染者和败血症患者中新型结核病 LAM 检测的评估
- 批准号:
10669787 - 财政年份:2022
- 资助金额:
$ 24.72万 - 项目类别:
Effects of TB and TB treatment on the pediatric intestinal microbiome
结核病和结核病治疗对儿童肠道微生物组的影响
- 批准号:
10042944 - 财政年份:2020
- 资助金额:
$ 24.72万 - 项目类别:
Effects of TB and TB treatment on the pediatric intestinal microbiome
结核病和结核病治疗对儿童肠道微生物组的影响
- 批准号:
10196992 - 财政年份:2020
- 资助金额:
$ 24.72万 - 项目类别:
Non-respiratory biomarkers to diagnose and monitor response in pediatric TB
用于诊断和监测儿童结核病反应的非呼吸生物标志物
- 批准号:
9116648 - 财政年份:2015
- 资助金额:
$ 24.72万 - 项目类别:
Non-respiratory biomarkers to diagnose and monitor response in pediatric TB
用于诊断和监测儿童结核病反应的非呼吸生物标志物
- 批准号:
8952359 - 财政年份:2015
- 资助金额:
$ 24.72万 - 项目类别:
Improving Pediatric Tb Diagnosis and Management in Tanzania
改善坦桑尼亚儿童结核病诊断和管理
- 批准号:
8374149 - 财政年份:2012
- 资助金额:
$ 24.72万 - 项目类别:
Improving Pediatric Tb Diagnosis and Management in Tanzania
改善坦桑尼亚儿童结核病诊断和管理
- 批准号:
8660027 - 财政年份:2012
- 资助金额:
$ 24.72万 - 项目类别:
Improving Pediatric Tb Diagnosis and Management in Tanzania
改善坦桑尼亚儿童结核病诊断和管理
- 批准号:
9061576 - 财政年份:2012
- 资助金额:
$ 24.72万 - 项目类别:
Improving Pediatric Tb Diagnosis and Management in Tanzania
改善坦桑尼亚儿童结核病诊断和管理
- 批准号:
8492026 - 财政年份:2012
- 资助金额:
$ 24.72万 - 项目类别:
Improving Pediatric Tb Diagnosis and Management in Tanzania
改善坦桑尼亚儿童结核病诊断和管理
- 批准号:
8849821 - 财政年份:2012
- 资助金额:
$ 24.72万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 24.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 24.72万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 24.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:
Standard Grant
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:














{{item.name}}会员




